
Agenus’ BOT/BAL Shows 42% 2-Year Survival in MSS CRC, Moves Toward FDA Registration
Agenus’ BOT/BAL Combo Delivers 42% Two-Year Survival in MSS Colorectal Cancer: Phase 3 Trial Aligned with FDA Agenus Inc., a pioneer in immuno-oncology, announced compelling new clinical results and regulatory progress for its combination therapy of botensilimab and balstilimab (BOT/BAL).…